Cibus Inc
cibus.comWhat Do They Do?
Develops gene-edited plant traits for agricultural crops for seed companies, and sustainable ingredients for consumer-products partners.
10-K for FY2025, filed Mar 17, 2026COMPANY OVERVIEWCibus is a leading agricultural biotechnology company that primarily uses proprietary gene editing technologies to develop…View ↗
- 4 - little as one year. Cibus’ primary trait business opportunities continue to broaden as key jurisdictions around the world more…View ↗
Cibus’ Secondary Program – Sustainable IngredientsAlongside its Rice program, Cibus also continues to advance its sustainable ingredients…View ↗
How Do They Make Money?
Collaborators pay for research and development under contract billing schedules, including upfront funding, cost reimbursements and milestone payments; royalties come when products containing licensed traits are sold.
10-K for FY2025, filed Mar 17, 2026Revenue is recognized from research collaboration agreements, sales of products, from licenses of technology, and from product development…View ↗
The Company receives payments from its collaborators based on billing schedules established in each contract. Upfront and other payments…View ↗
License fees, non-refundable upfront fees, and funding of research activities are considered fixed, while milestone payments are identified…View ↗
OVERVIEW AND BUSINESS UPDATECibus is a leading agricultural biotechnology company that uses proprietary gene editing technologies to…View ↗
$3.6M
-
10-K for FY2025, filed Mar 17, 2026
$3.6M ↗
Who Are Their Customers?
Seed companies work with Cibus to develop traits for their seed products, while a consumer-packaged-goods partner supports sustainable-ingredient development.
10-K for FY2025, filed Mar 17, 2026
Do Revenues Turn Into Profits?
No. It lost $127.1M in FY2025.
10-K for FY2025, filed Mar 17, 2026
−$97.5MView ↗
10-K for FY2025, filed Mar 17, 2026
−$127.1MView ↗
10-K for FY2025, filed Mar 17, 2026
−$51.2MView ↗
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 13, 2026
−$22.1MView ↗
- ▼ −13% (Loss)
- vs −$25.4M in Q2 FY2025
-
Aug 13, 2026
Cibus and Interoc expanded their planned Rice-trait relationship
The amended letter of intent expands the planned scope from two Rice traits to five, adding three traits for development and possible commercialization.
Sources
8-K, filed Aug 13, 2026
Weed Management (HT1 and HT3) in Rice During the quarter, Cibus advanced development on both of its Rice herbicide tolerance traits. This…View ↗
-
Jun 9, 2026
Craig Wichner appointed chief executive
Peter Beetham returned to his President and Chief Operating Officer role.
Sources
8-K, filed Jun 9, 2026
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of…View ↗
Focus shifted to seed traits
Calyxt described engineering plant-based chemistries for manufacture in its BioFactory system as its primary focus, serving customers across several end markets; Cibus describes crop productivity traits for seed companies as its primary business, with sustainable ingredients as a separate program.
10-K for FY2022, filed Mar 2, 2023 10-K for FY2025, filed Mar 17, 2026
Who Do They Compete With?
Competes with BASF, Bayer Crop Science, Corteva AgriScience, Syngenta, Inari Agriculture, and Pairwise Plants
10-K for FY2025, filed Mar 17, 2026The market for agricultural productivity traits is highly competitive, and Cibus faces significant competition. The development of…View ↗
Loading...
